Key result
Warfarin treatment after coronary stenting was associated with an increased risk of the primary composite endpoint (OR 1.7; 95% CI 1.0-3.0; P=0.05) and major bleeding.
Why the study?
Does combined antiplatelet-warfarin therapy improve ischemic outcomes and safety in patients requiring long-term anticoagulation after coronary stenting?
Population
Patients requiring long-term anticoagulation on warfarin therapy who underwent percutaneous coronary…
Comparison
Warfarin therapy combined with antiplatelet… vs Age- and sex-matched control group with similar…
Design
Cohort
Follow-up
12 months
Authors
Loading...
May increase ischemic and bleeding risks post-stenting; leaves open optimal antithrombotic regimens for randomized evaluation.
Cohort
Yes
Does combined antiplatelet-warfarin therapy improve ischemic outcomes and safety in patients requiring long-term anticoagulation after coronary stenting?
Effect estimate: OR 1.7 (95% CI 1.0-3.0)
p-value: p=0.05
In patients undergoing PCI, long-term warfarin therapy combined with antiplatelets is associated with increased risks of both ischemic events and major bleeding compared to matched controls.
Karjalainen et al. (2007) conducted a cohort in Coronary stenting in patients requiring long-term anticoagulation. Warfarin therapy vs. Age- and sex-matched control group was evaluated on Occurrence of death, myocardial infarction, target vessel revascularization, or stent thrombosis at 12 months (OR 1.7, 95% CI 1.0-3.0, p=0.05). Warfarin treatment after coronary stenting was associated with an increased risk of the primary composite endpoint (OR 1.7; 95% CI 1.0-3.0; P=0.05) and major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: